Article Versions Notes

Berdugo M, Delaunay K, Lebon C, Naud M-C, Radet L, Zennaro L, Picard E, Daruich A, Beltrand J, Kermorvant-Duchemin E, et al. Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model. Pharmaceutics. 2021; 13(7):1095. https://doi.org/10.3390/pharmaceutics13071095

Berdugo, Marianne, Kimberley Delaunay, Cécile Lebon, Marie-Christine Naud, Lolita Radet, Léa Zennaro, Emilie Picard, Alejandra Daruich, Jacques Beltrand, Elsa Kermorvant-Duchemin, and et al. 2021. "Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model" Pharmaceutics 13, no. 7: 1095. https://doi.org/10.3390/pharmaceutics13071095

Berdugo, M., Delaunay, K., Lebon, C., Naud, M.-C., Radet, L., Zennaro, L., Picard, E., Daruich, A., Beltrand, J., Kermorvant-Duchemin, E., Polak, M., Crisanti, P., & Behar-Cohen, F. F. (2021). Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model. Pharmaceutics, 13(7), 1095. https://doi.org/10.3390/pharmaceutics13071095